Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of cannabidiol oral solution in Rett syndrome
2019-001605-24Phase 3Unknown
- Sponsor
- GW Pharmaceuticals
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cannabidiol in Rett syndrome (RTT), sponsored by GW Pharmaceuticals. Primary endpoint: Long-term safety of GWP42003-P. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on 2019-001605-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001605-24.